Ethambutol Optic Neuropathy in a Hemodialysis Patient Receiving a Guideline-Recommended Dose

Scoville, Bridget A.; Lott, Lindsey B. De; Trobe, Jonathan D.; Mueller, Bruce A.

doi:10.1097/wno.0000000000000075

Cited by 5 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scoville et al recently presented a case of EMB optic neuropathy in a haemodialysis patient who received the guideline-recommended dose of 1200 mg EMB three times a week, which already led to toxicity. 11 We conclude that after an initial dose, as for patients without renal impairment (15 mg/kg/day), therapeutic drug monitoring should be used to guide EMB dosing in patients undergoing extended daily dialysis. Individualized medicine requires this additional effort.…”

Section: Discussionmentioning

confidence: 90%

Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment

Strunk

Ciesek

Schmidt

et al. 2016

International Journal of Infectious Diseases

View full text Add to dashboard Cite

The dosing of drugs in critically ill patients undergoing renal replacement therapy is based on limited data. We report for the first time single- and multiple-dose pharmacokinetics of ethambutol (EMB), which is cleared renally to 80%, and rifampicin (RIF), which is cleared renally to <30%, in a patient requiring both extracorporeal membrane oxygenation (ECMO) and renal replacement therapy. Extended dialysis removed a considerable amount of both EMB and RIF, with a dialyser plasma clearance ranging between 37 and 95 ml/min for EMB and between 39 and 53 ml/min for RIF. The EMB peak level (3h after a 2-h infusion) using a dose of 1000 mg/day on the first day of treatment was 2.3mg/l, which is in the low therapeutic range (2-5mg/l). Doubling the dose to 2000 mg/day resulted in peak levels slightly to markedly above the recommended range. There was no detectable effect of the ECMO membrane on the removal of both drugs. After an initial dose as for patients without renal impairment (15 mg/kg/day), therapeutic drug monitoring should be used to guide EMB dosing in patients undergoing extended daily dialysis.

show abstract

Section: Discussionmentioning

confidence: 90%